Detalhe da pesquisa
1.
Reduction of immunosuppression combined with whole-brain radiotherapy and concurrent systemic rituximab is an effective yet toxic treatment of primary central nervous system post-transplant lymphoproliferative disorder (pCNS-PTLD): 14 cases from the prospective German PTLD registry.
Ann Hematol
; 100(8): 2043-2050, 2021 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-33973053